肿瘤诊疗实践中创新疗法的采用——来自免疫治疗的证据
该队列研究利用2010至2017年医疗保险按服务付费受益人的6个月化疗 episodes 数据,评估美国肿瘤诊疗实践对免疫治疗的采用情况。研究纳入71 659个 episodes、1 732个肿瘤诊疗实践,分析黑色素瘤、肾癌、肺癌和头颈癌患者。多数实践在FDA批准后2年内采用免疫治疗,但农村实践和医师数1至5人的实践采用率较低。
要点
- 多数肿瘤诊疗实践在FDA批准免疫治疗后2年内采用该疗法。
- 农村实践采用率比城市实践低11个百分点(95%CI,-16至-6)。
- 医师数1至5人的实践采用率比6人及以上实践低27个百分点(95%CI,-32至-22)。
核心结论
- 在这项医疗保险索赔队列研究中,实践特征尤其是实践规模和农村位置与免疫治疗的采用相关。
- 这些发现提示,在获取治疗癌症的重要创新疗法方面可能存在地理差异。
研究设计与样本
- 这项队列研究使用2010至2017年间接受6个月化疗 episodes 的医疗保险按服务付费受益人的数据,数据分析时间为2021年1月19日至2022年9月28日。
- 研究纳入美国FDA在研究期间批准免疫治疗的癌症类型患者:黑色素瘤、肾癌、肺癌和头颈癌患者。
- 数据包括1 732个肿瘤诊疗实践的71 659个 episodes;其中264个实践(15%)为农村,900个(52%)为独立实践,492个(28%)有1至5名医师。
主要发现
- 多数实践在FDA批准后2年内采用免疫治疗,但不同实践类型的采用率存在实质性差异。
- FDA批准后,农村实践的免疫治疗采用率比城市实践低11个百分点(95%CI,-16至-6)。
- 医师数1至5人的实践采用率比6人及以上实践低27个百分点(95%CI,-32至-22)。
- 独立实践和非学术系统实践的采用率相似,但均低于学术系统:独立实践差异为-6个百分点(95%CI,-9至-3),非学术系统差异为-9个百分点(95%CI,-11至-6)。
关键数值与推荐
- 采用率估计使用多变量线性模型,并调整患者特征(年龄、性别、种族和民族、癌症类型、Charlson合并症指数和中位家庭收入)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Immunotherapies reflect an important breakthrough in cancer treatment, substantially improving outcomes for patients with a variety of cancer types, yet little is known about which practices have adopted this novel therapy or the pace of adoption. OBJECTIVE: To assess adoption of immunotherapies across US oncology practices and examine variation in adoption by practice type. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from Medicare fee-for-service beneficiaries undergoing 6-month chemotherapy episodes between 2010 and 2017. Data were analyzed January 19, 2021, to September 28, 2022, for patients with cancer types for which immunotherapy was approved by the US Food and Drug Administration (FDA) during the study period: melanoma, kidney cancer, lung cancer, and head and neck cancer. EXPOSURES: Oncology practice location (rural vs urban), affiliation type (academic system, nonacademic system, independent), and size (1 to 5 physicians vs 6 or more physicians). MAIN OUTCOMES AND MEASURES: The primary outcome was whether a practice adopted immunotherapy. Adoption rates for each practice type were estimated using multivariate linear models that adjusted for patient characteristics (age, sex, race and ethnicity, cancer type, Charlson Comorbidity Index, and median household income). RESULTS: Data included 71 659 episodes at 1732 oncology practices. Of these, 264 practices (15%) were rural, 900 (52%) were independent, and 492 (28%) had 1 to 5 physicians. Most practices adopted immunotherapy within 2 years of FDA approval, but there was substantial variation in adoption rates across practice types. After FDA approval, adoption of immunotherapy was 11 (95% CI, -16 to -6) percentage points lower at rural practices than urban practices and 27 (95% CI, -32 to -22) percentage points lower at practices with 1 to 5 physicians than practices with 6 or more physicians. Adoption rates were similar at independent practices and nonacademic systems; however, both practice types had lower adoption than academic systems (independent practice difference, -6 [95% CI, -9 to -3] percentage points; nonacademic systems difference, -9 [95% CI, -11 to -6] percentage points). CONCLUSIONS AND RELEVANCE: In this cohort study of Medicare claims, practice characteristics, especially practice size and rural location, were associated with adoption of immunotherapy. These findings suggest that there may be geographic disparities in access to important innovations for treating patients with cancer.
引用
- Carroll CE, Landrum MB, Wright AA, et al. Adoption of Innovative Therapies Across Oncology Practices-Evidence From Immunotherapy. JAMA Oncol. 2023. PMID: 36602811. doi:10.1001/jamaoncol.2022.6296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。